Chemistry:Tacalcitol
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | (1α,24R)-1,24-Dihydroxyvitamin D3 |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Topical |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H44O3 |
| Molar mass | 416.646 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Tacalcitol (1,24-dihydroxyvitamin D3) is a synthetic vitamin D3 analog.[1] Tacalcitol is marketed under several names, including Curatoderm and Bonalfa.
It is on the World Health Organization's List of Essential Medicines.[2]
Mechanism
Tacalcitol reduces excessive cell turnover in the epidermis by interacting with vitamin D receptors on keratinocytes.[3][4]
Uses
It is usually prescribed by a general practitioner or dermatologist for the treatment of psoriasis, chronic chapped lips and other severe dry skin conditions because of its ability to reduce excessive skin cell turnover.[1] It is available as an ointment or lotion.
It has also been used for vitiligo[5][6] and Hailey-Hailey disease.[7]
References
- ↑ 1.0 1.1 "Tacalcitol". Drugs 54 (2): 265–71; discussion 272. August 1997. doi:10.2165/00003495-199754020-00005. PMID 9257082.
- ↑ World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. WHO/MHP/HPS/EML/2021.02.
- ↑ "Effect of 1,24R-dihydroxyvitamin D3 on the growth of human keratinocytes". The Journal of Dermatology 17 (2): 97–103. February 1990. doi:10.1111/j.1346-8138.1990.tb03714.x. PMID 2158504.
- ↑ "Tacalcitol, an active vitamin D3, induces nerve growth factor production in human epidermal keratinocytes". Skin Pharmacol. Appl. Skin Physiol. 14 (4): 226–33. 2001. doi:10.1159/000056351. PMID 11464105. http://content.karger.com/produktedb/produkte.asp?typ=fulltext&file=sph14226.
- ↑ "Tacalcitol and narrow-band phototherapy in patients with vitiligo". Clin. Exp. Dermatol. 31 (2): 200–5. March 2006. doi:10.1111/j.1365-2230.2005.02037.x. PMID 16487090.
- ↑ "Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation". Current Drug Targets 9 (4): 345–59. April 2008. doi:10.2174/138945008783954970. PMID 18393827.
- ↑ "1alpha,24-dihydroxyvitamin D3 (tacalcitol) is effective against Hailey-Hailey disease both in vivo and in vitro". Br. J. Dermatol. 139 (5): 897–901. November 1998. doi:10.1046/j.1365-2133.1998.02522.x. PMID 9892963.
 |  |
